1. **Meeting formalities**
Carl-Henrik Heldin opened the meeting and informed about upcoming changes amongst the members.

Decisions:
- *The SciLifeLab board appointed Gunilla Westergren-Thorsson to approve the minutes of the present meeting, in addition to the chair.*
- *The SciLifeLab board approved the minutes from meeting no 33, after a correction in Appendix C: when adding the figures in row 1-22 the total sum is 57 809 kSEK.*

2. **Update from the Director**
Olli Kallioniemi presented an update from SciLifeLab. Focus was mostly on the 2018 statistics and the new figures that have been made for the IAB report to demonstrate the past performance and present status of SciLifeLab.

3. **IAB report: General discussion and approval of the process**
VC-2019-0008

The International Advisory Board (IAB) of SciLifeLab will come for a site-visit on March 13-15, 2019 in Solna and Uppsala. The MG and Operations Office have, together with the host universities, and the SciLifeLab community, prepared a thorough description of the SciLifeLab development as well as strategic plans for the future.

Olli Kallioniemi presented the IAB report.
Decisions:
- The SciLifeLab board approved the final program for the IAB visit (after some revisions) and the participants in each session.
- The SciLifeLab board approved the process on how the IAB document is handled (publicity) and the specific sections that will be discussed in detail before approval.

3a. IAB report: Approval of the strategy and future plans section
VC-2019-0008

Olli Kallioniemi gave an update of the section SciLifeLab Strategy and Future Plans which describes the plans for strategic development of SciLifeLab over the next few years.

Decision:
- The SciLifeLab board approved the document conditionally (after comments have been taken into account).

3b. IAB report: Approval of the updated versions of responses to the IAB 2017 questions
VC-2019-0008

After its last visit in 2017, the IAB provided SciLifeLab with 42 specific comments to act upon. The board approved the responses to the IAB 2017 comments at their meeting in November 2017. Olli Kallioniemi informed about the revised and updated version of the responses as of January 2019.

Decision:
- The SciLifeLab board approved the document in principle (after revisions have been taken into account).

3c. IAB report: Approval of the white papers (for the IAB meeting only)
VC-2019-0008

The IAB suggested at their last visit that the SciLifeLab management should write three white papers on topics that were considered to be of key importance for the future of SciLifeLab. These topics are research integrity, industrial collaboration and clinical collaborations.

Olli Kallioniemi gave an update regarding the white papers that have now been written.

Decision:
- The SciLifeLab board approved the three white papers in principle (after revisions have been taken into account) as documents to be provided as drafts for the IAB meeting.
4. **SciLifeLab annual report 2018 – approval**
   VC-2019-0009

Jenny Alfredsson presented some figures from the draft annual report for 2018.

**Decision:**
- *The SciLifeLab board approved the annual report 2018 to be presented for the KTH board for final approval.*

5. **Update on the preparations for the 2020 infrastructure evaluation**

Annika Jenmalm Jensen gave an update on the preparations for the next international evaluation regarding SciLifeLab infrastructure that will take place in 2020.

6. **Appointment of Infrastructure Director**
   VC-2019-0011

Annika Jenmalm Jensen left the room during this point.

Olli Kallioniemi informed the board about the appointment of Infrastructure Director.

**Decision:**
- *The SciLifeLab board decided to appoint Annika Jenmalm Jensen as Infrastructure Director until June 30, 2020.*

7. **Upcoming strategy meeting**

Olli Kallioniemi informed about the plans for the board strategy meeting Wednesday May 29, 2019. Departing members of the board are welcome to attend the meeting as well as Scientific Directors and Integration Directors.

8. **Director’s decisions 2018**
   VC-2018-0002

‘Delegationsordning för SciLifeLab’ regulates the decision rights for the SciLifeLab board and how these can be delegated. Olli Kallioniemi informed about delegated decisions 2018.

**Decision:**
- *The SciLifeLab board noted the information to the minutes.*

9. **SciLifeLab 5/10 year’s anniversary**

Olli Kallioniemi informed about the suggestion to organize a celebration of 5/10 year’s anniversary to promote SciLifeLab’s achievements and promote its continuation over the next years. Friday September 20, 2019, is scheduled for the event.

**Decision:**
- *The SciLifeLab board decided that Anders Karlhede will be representative for the board when planning the event.*
10. **Drug Discovery and Development – approval of distribution of funding**

   VC-2019-0005

The SciLifeLab board approved (per capsulam 2018-10-22) the budget for the national infrastructure and for Drug Discovery and Development (DDD). The DDD management was then asked to suggest a distribution of the funding to the facilities within DDD to be approved by the board.

Annika Jenmalm Jensen informed about the proposed distribution of funding to the facilities within DDD.

**Decision:**
- The SciLifeLab board approved the suggested distribution of funding (appendix A).

11. **Other issues**

11a. **Expensive Instruments Call 2019**

   VC-2019-0010

Annika Jenmalm Jensen gave an update of the preparations for the Expensive Instruments Call 2019.

11b. **Result of VR behovsinventering and next RFI call of infrastructures of national interest**

Annika Jenmalm Jensen gave an update regarding VR behovsinventering and the next RFI call.

**Upcoming meetings**
- May 29, 2019 at 11.00-17.00 (exact times TBD) in Uppsala (followed by dinner)
- September 25, 2019 at 10.00-15.00 in Stockholm (Earth, Gamma 2)
- November 11, 2019 at 10.00-15.00 in Stockholm (Earth, Gamma 2)

Anna Höglund Rehn, secretary

Minutes approved by:

__________________________
Carl-Henrik Heldin

__________________________
Gunilla Westergren-Thorsson
### Appendix A

SciLifeLab DDD funding 2019

#### DDD Sthlm/Uppsala

<table>
<thead>
<tr>
<th>Platform</th>
<th>Facility</th>
<th>Lund</th>
<th>KTH</th>
<th>KI</th>
<th>SU</th>
<th>UU</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Discovery and Development</td>
<td>ADME</td>
<td></td>
<td>5 423 697</td>
<td></td>
<td></td>
<td></td>
<td>4 556 532</td>
</tr>
<tr>
<td></td>
<td>Biochemical and Cellular Assays</td>
<td></td>
<td>5 423 697</td>
<td></td>
<td></td>
<td></td>
<td>5 423 697</td>
</tr>
<tr>
<td></td>
<td>Biophysical Screening and Characterization</td>
<td>2 389 346</td>
<td>2 389 346</td>
<td></td>
<td></td>
<td></td>
<td>4 778 692</td>
</tr>
<tr>
<td></td>
<td>Human Antibody Therapeutics</td>
<td>5 392 926</td>
<td>5 392 926</td>
<td></td>
<td></td>
<td></td>
<td>10 785 852</td>
</tr>
<tr>
<td></td>
<td>In Vitro and Systems Pharmacology</td>
<td>3 071 485</td>
<td>3 071 485</td>
<td></td>
<td></td>
<td></td>
<td>6 142 970</td>
</tr>
<tr>
<td></td>
<td>Medicinal Chemistry-Hit2Lead</td>
<td>6 704 529</td>
<td>6 704 529</td>
<td></td>
<td></td>
<td></td>
<td>13 409 058</td>
</tr>
<tr>
<td></td>
<td>Medicinal Chemistry-Lead Identification</td>
<td>3 584 939</td>
<td>3 584 939</td>
<td></td>
<td></td>
<td></td>
<td>7 169 878</td>
</tr>
<tr>
<td></td>
<td>Protein Expression and Characterization</td>
<td>4 499 932</td>
<td>4 499 932</td>
<td></td>
<td></td>
<td></td>
<td>8 999 864</td>
</tr>
<tr>
<td></td>
<td>Target Product Profiling&amp;Drug Safety Assessment</td>
<td>6 700 000</td>
<td>3 181 471</td>
<td>4 170 161</td>
<td>8 023 632</td>
<td>18 054 874</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Compound Center*</td>
<td>1 000 000</td>
<td>1 000 000</td>
<td></td>
<td></td>
<td></td>
<td>2 000 000</td>
</tr>
<tr>
<td>National Infra funding</td>
<td>Compound Center</td>
<td>1 000 000</td>
<td>1 000 000</td>
<td></td>
<td></td>
<td></td>
<td>2 000 000</td>
</tr>
<tr>
<td>Lund</td>
<td>U-READ</td>
<td>2 000 000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 000 000</td>
</tr>
<tr>
<td>Sum DDD</td>
<td></td>
<td>2 000 000</td>
<td>10 532 839</td>
<td>5 181 471</td>
<td>12 128 226</td>
<td>17 672 464</td>
<td>47 515 000</td>
</tr>
</tbody>
</table>

*Compound center is a joint CBCS and DDD facility*